Full Press Release Details
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP)
~A$1.13 million R&D Tax Incentive
SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the
Company ), is pleased to announce that it has received a A$1,134,882 cash rebate from the Australian Federal Government s R&D tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible R&D
activities conducted in the 2022 fiscal year, mainly related to the Company s TACTI-002 and TACTI-003 clinical study using its lead compound eftilagimod alpha
( efti or IMP321 ), conducted in Australia.
This follows approval from AusIndustry of Immutep s application for an
Advance/Overseas Finding. Due to the Advance Finding, both Immutep s Australian and overseas research and development activities related to the TACTI-002 and
TACTI-003 Australian sites were eligible for the R&D Tax Incentive.
Immutep also receives the French CIR tax
incentive through its subsidiary Immutep S.A.S in respect of expenditure incurred on eligible R&D activities conducted in the European Union.
will apply the non-dilutive funding towards furthering its current active clinical trial programs for its lead product candidate, efti. The expected cash reach of the Company extends into early calendar year
Immutep is a clinical-stage
biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Australian Investors/Media:
+61 (0)406 759 268; cstrong@citadelmagnus.com
U.S. Investors/Media:
Chris Basta, VP, Investor
Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com
This announcement was authorised for release by the CEO of Immutep Limited.
Immutep Limited, Level 33, Australia Square
264 George Street, Sydney NSW 2000